To determine the clinical significance, we analyzed in MH BRCA retrospectively in 149 BRCA1/2 variant positive cases from a total of 346 patients with breast, ovarian, or prostate cancer, which were sequenced at the YCH to test for an indication of HBOC or HPC syndrome, respectively. Here, BRCA1 is linked to prostate cancer.